Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits.

Sudo M, Li Y, Hiro T, Takayama T, Mitsumata M, Shiomi M, Sugitani M, Matsumoto T, Hao H, Hirayama A

Atherosclerosis23 Jun 2017Cited by 44 (Europe PMC)

PMID28693828DOI10.1016/j.atherosclerosis.2017.06.920PepBankPUB-28693828

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, lixisenatide increased fibrotic plaque components versus saline: 66.30 ± 2.06% versus 75.14 ± 2.62% in the reported pair (p < 0.01).
In plain wordsIn rabbits, lixisenatide increased fibrotic plaque components compared with saline.
Peptide
Lixisenatide
Outcome
IncreaseIVUS fibrotic plaque area
Study
Rabbitn = 10
Watanabe heritable hyperlipidemic rabbits
Comparator
Normal saline
Outcome group
Atherosclerotic plaque composition · Cardiovascular
Studied dose
30 nmoL/kg/day · osmotic pump · 12 weeksAs given in this study (Rabbit).
Source sentences
Summary
iMAP-IVUS analysis revealed larger fibrotic plaque components and smaller necrotic and calcified plaque components in the GLP-1 group than in the control group; %fibrotic area: 66.30 ± 2.06% vs. 75.14 ± 2.62%, p < 0.01,
2 context sentences(design, population, supporting numbers)
Summary · context
After confirmation of atherosclerotic plaques in brachiocephalic arteries by iMap intravascular ultrasound (iMAP-IVUS), GLP-1 receptor agonist lixisenatide was administered to WHHL rabbits at 30 nmoL/kg/day for 12 weeks by osmotic pump.
Summary · context
An equal volume of normal saline was administered in a control group.
Report a problemFND-2869382801
02AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, lixisenatide reduced necrotic plaque components versus saline: 23.25 ± 1.87% versus 16.17 ± 2.27% in the reported pair (p = 0.02).
In plain wordsIn rabbits, lixisenatide reduced necrotic plaque components compared with saline.
Peptide
Lixisenatide
Outcome
DecreaseIVUS necrotic plaque area
Study
Rabbitn = 10
Watanabe heritable hyperlipidemic rabbits
Comparator
Normal saline
Outcome group
Atherosclerotic plaque composition · Cardiovascular
Studied dose
30 nmoL/kg/day · osmotic pump · 12 weeksAs given in this study (Rabbit).
Source sentences
Summary
%necrotic area: 23.25 ± 1.87% vs. 16.17 ± 2.27%, p = 0.02,
2 context sentences(design, population, supporting numbers)
Summary · context
After confirmation of atherosclerotic plaques in brachiocephalic arteries by iMap intravascular ultrasound (iMAP-IVUS), GLP-1 receptor agonist lixisenatide was administered to WHHL rabbits at 30 nmoL/kg/day for 12 weeks by osmotic pump.
Summary · context
An equal volume of normal saline was administered in a control group.
Report a problemFND-2869382802
03AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, lixisenatide reduced calcified plaque components versus saline: 2.15 ± 0.24% versus 1.00 ± 0.18% in the reported pair (p < 0.01).
In plain wordsIn rabbits, lixisenatide reduced calcified plaque components compared with saline.
Peptide
Lixisenatide
Outcome
DecreaseIVUS calcified plaque area
Study
Rabbitn = 10
Watanabe heritable hyperlipidemic rabbits
Comparator
Normal saline
Outcome group
Atherosclerotic plaque composition · Cardiovascular
Studied dose
30 nmoL/kg/day · osmotic pump · 12 weeksAs given in this study (Rabbit).
Source sentences
Summary
%calcified area: 2.15 ± 0.24% vs. 1.00 ± 0.18%, p < 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
After confirmation of atherosclerotic plaques in brachiocephalic arteries by iMap intravascular ultrasound (iMAP-IVUS), GLP-1 receptor agonist lixisenatide was administered to WHHL rabbits at 30 nmoL/kg/day for 12 weeks by osmotic pump.
Summary · context
An equal volume of normal saline was administered in a control group.
Report a problemFND-2869382803
04AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, lixisenatide increased smooth muscle cell area versus saline: 6.93 ± 0.31% versus 8.14 ± 0.48% in the reported pair (p = 0.02).
In plain wordsIn rabbits, lixisenatide increased smooth muscle cell area in plaques compared with saline.
Peptide
Lixisenatide
Outcome
IncreaseHistological smooth muscle cell area
Study
Rabbitn = 10
Watanabe heritable hyperlipidemic rabbits
Comparator
Normal saline
Outcome group
Atherosclerotic plaque composition · Cardiovascular
Studied dose
30 nmoL/kg/day · osmotic pump · 12 weeksAs given in this study (Rabbit).
Source sentences
Summary
%SMC area: 6.93 ± 0.31% vs. 8.14 ± 0.48%, p = 0.02;
3 context sentences(design, population, supporting numbers)
Summary · context
Histological analysis confirmed that GLP-1 receptor agonist treatment improved smooth muscle cell (SMC)-rich plaque with increased fibrotic content.
Summary · context
After confirmation of atherosclerotic plaques in brachiocephalic arteries by iMap intravascular ultrasound (iMAP-IVUS), GLP-1 receptor agonist lixisenatide was administered to WHHL rabbits at 30 nmoL/kg/day for 12 weeks by osmotic pump.
Summary · context
An equal volume of normal saline was administered in a control group.
Report a problemFND-2869382804
05AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, lixisenatide reduced plaque macrophage area versus saline: 9.11 ± 0.80% versus 6.19 ± 0.85% in the reported pair (p < 0.01).
In plain wordsIn rabbits, lixisenatide reduced plaque macrophage infiltration compared with saline.
Peptide
Lixisenatide
Outcome
DecreaseHistological macrophage area
Study
Rabbitn = 10
Watanabe heritable hyperlipidemic rabbits
Comparator
Normal saline
Outcome group
Atherosclerotic plaque composition · Cardiovascular
Studied dose
30 nmoL/kg/day · osmotic pump · 12 weeksAs given in this study (Rabbit).
Source sentences
Summary
%macrophage area: 9.11 ± 0.80% vs. 6.19 ± 0.85%, p < 0.01;
2 context sentences(design, population, supporting numbers)
Summary · context
After confirmation of atherosclerotic plaques in brachiocephalic arteries by iMap intravascular ultrasound (iMAP-IVUS), GLP-1 receptor agonist lixisenatide was administered to WHHL rabbits at 30 nmoL/kg/day for 12 weeks by osmotic pump.
Summary · context
An equal volume of normal saline was administered in a control group.
Report a problemFND-2869382805
06AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, lixisenatide increased plaque fibrotic area versus saline: 54.75 ± 1.63% versus 69.60 ± 2.12% in the reported pair (p = 0.02).
In plain wordsIn rabbits, lixisenatide increased plaque fibrotic area compared with saline.
Peptide
Lixisenatide
Outcome
IncreaseHistological fibrotic area
Study
Rabbitn = 10
Watanabe heritable hyperlipidemic rabbits
Comparator
Normal saline
Outcome group
Atherosclerotic plaque composition · Cardiovascular
Studied dose
30 nmoL/kg/day · osmotic pump · 12 weeksAs given in this study (Rabbit).
Source sentences
Summary
%fibrotic area: 54.75 ± 1.63% vs. 69.60 ± 2.12%, p = 0.02;
3 context sentences(design, population, supporting numbers)
Summary · context
Histological analysis confirmed that GLP-1 receptor agonist treatment improved smooth muscle cell (SMC)-rich plaque with increased fibrotic content.
Summary · context
After confirmation of atherosclerotic plaques in brachiocephalic arteries by iMap intravascular ultrasound (iMAP-IVUS), GLP-1 receptor agonist lixisenatide was administered to WHHL rabbits at 30 nmoL/kg/day for 12 weeks by osmotic pump.
Summary · context
An equal volume of normal saline was administered in a control group.
Report a problemFND-2869382806
07AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, lixisenatide reduced plaque calcified area versus saline: 3.25 ± 0.67% versus 0.75 ± 0.15% in the reported pair (p = 0.02).
In plain wordsIn rabbits, lixisenatide reduced plaque calcification compared with saline.
Peptide
Lixisenatide
Outcome
DecreaseHistological calcified area
Study
Rabbitn = 10
Watanabe heritable hyperlipidemic rabbits
Comparator
Normal saline
Outcome group
Atherosclerotic plaque composition · Cardiovascular
Studied dose
30 nmoL/kg/day · osmotic pump · 12 weeksAs given in this study (Rabbit).
Source sentences
Summary
%calcified area: 3.25 ± 0.67% vs. 0.75 ± 0.15%, p = 0.02).
2 context sentences(design, population, supporting numbers)
Summary · context
After confirmation of atherosclerotic plaques in brachiocephalic arteries by iMap intravascular ultrasound (iMAP-IVUS), GLP-1 receptor agonist lixisenatide was administered to WHHL rabbits at 30 nmoL/kg/day for 12 weeks by osmotic pump.
Summary · context
An equal volume of normal saline was administered in a control group.
Report a problemFND-2869382807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.